急诊就诊确诊阿片类药物过量患者中苯二氮䓬类合并暴露情况
该研究基于毒物调查联盟Fentalog研究,在10个急诊站点(2020年9月至2023年12月)对确诊阿片过量患者的废弃血清样本进行LC-QTOF-MS分析,检测1200余种新型精神活性物质。在1427例阿片阳性的患者中,29.0%可检出苯二氮䓬类,其中20.5%为处方苯二氮䓬、8.5%为新型苯二氮䓬。最常见处方苯二氮䓬为阿普唑仑(39.3%),最常见新型苯二氮䓬为溴唑仑(占新型苯二氮䓬的46.3%)。新型苯二氮䓬组患者中位年龄34岁,低于无苯二氮䓬组(40岁)和处方苯二氮䓬组(41岁;p=0.001)。无苯二氮䓬组接受纳洛酮更频繁(p=0.02),而新型苯二氮䓬合并暴露与更高纳洛酮无反应率相关(p=0.03)。校正年龄、性别、种族和民族以及处方苯二氮䓬和/或芬太尼存在后,新型苯二氮䓬组较阿片单药组需要机械通气的比值比升高(aOR 2.14;95%CI 1.07,4.05)。
要点
- 确诊阿片过量急诊患者中29.0%可检出苯二氮䓬类,其中新型苯二氮䓬占8.5%,提示合并暴露常见。
- 新型苯二氮䓬合并暴露与更高纳洛酮无反应率相关(p=0.03),抢救时需警惕纳洛酮反应不佳。
- 校正混杂后,新型苯二氮䓬组较阿片单药组机械通气需求比值比升高(aOR 2.14;95%CI 1.07,4.05)。
- 无苯二氮䓬组接受纳洛酮更频繁(p=0.02),而新型苯二氮䓬组纳洛酮无反应率更高。
- 新型苯二氮䓬组中位年龄34岁,低于无苯二氮䓬组40岁和处方苯二氮䓬组41岁(p=0.001)。
适用人群与场景
- 在10个急诊站点就诊、疑似阿片过量且血清样本中检出阿片类药物的患者(n=1427)。
研究设计与关键结果
- 研究类型为观察性研究(毒物调查联盟Fentalog研究),在10个急诊站点开展,纳入2020年9月至2023年12月确诊阿片过量患者,共1427例阿片阳性样本。
- 1427例阿片阳性患者中29.0%可检出苯二氮䓬类,20.5%为处方苯二氮䓬,8.5%为新型苯二氮䓬。
- 最常见处方苯二氮䓬为阿普唑仑(39.3%);最常见新型苯二氮䓬为溴唑仑(占新型苯二氮䓬的46.3%)。
- 新型苯二氮䓬组中位年龄34岁,低于无苯二氮䓬组40岁和处方苯二氮䓬组41岁(p=0.001)。
- 无苯二氮䓬组接受纳洛酮更频繁(p=0.02);新型苯二氮䓬合并暴露与更高纳洛酮无反应率相关(p=0.03)。
- 校正年龄、性别、种族和民族以及处方苯二氮䓬和/或芬太尼存在后,新型苯二氮䓬组较阿片单药组需要机械通气的比值比升高(aOR 2.14;95%CI 1.07,4.05)。
证据类型、等级与局限
- 证据类型:观察性研究(毒物调查联盟Fentalog研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊接诊确诊阿片过量患者时,近三成合并苯二氮䓬暴露,应考虑到合并暴露可能影响纳洛酮反应和呼吸支持需求。
- 新型苯二氮䓬合并暴露患者纳洛酮无反应率更高、机械通气比值比升高(aOR 2.14;95%CI 1.07,4.05),对纳洛酮反应不佳者需警惕并准备气道支持。
- 新型苯二氮䓬暴露者中位年龄34岁,较无苯二氮䓬组和处方苯二氮䓬组更年轻,年轻阿片过量患者也应考虑新型苯二氮䓬合并暴露。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Simultaneous exposure to both benzodiazepines and opioids can lead to synergistic respiratory depression, complicating overdose management. Our objective was to report on the detection of prescription and novel benzodiazepine co-exposures among patients treated in emergency departments (EDs) with suspected opioid overdoses. We aimed to describe novel benzodiazepine exposures in this population and to compare the clinical severity of co-exposure to benzodiazepines and opioids versus opioids alone.
METHODS: This study utilized data from the Toxicology Investigators Consortium (ToxIC) Fentalog Study, an observational study at 10 ED sites (Sept 2020-Dec 2023). Waste serum samples were analyzed using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) for the presence of over 1200 novel psychoactive substances (NPS), drugs, therapeutics, and metabolites. Analyses included demographics, clinical severity, and outcomes among those with prescription benzodiazepines, novel benzodiazepines, or no benzodiazepines.
RESULTS: Among the patients with opioids present (n = 1427), 29.0% of patients had detectable benzodiazepines. 20.5% of patients had detectable prescription benzodiazepines, and 8.5% of patients had detectable novel benzodiazepines. The most commonly detected prescription benzodiazepine was alprazolam (39.3%); the most common novel benzodiazepine was bromazolam (46.3% of novel benzodiazepines). The median age of those with novel benzodiazepines was 34, which was younger than those without benzodiazepines (40) and those with prescription benzodiazepines (41; p = 0.001). Patients without benzodiazepines received naloxone more frequently (p = 0.02), while novel benzodiazepine co-exposure was associated with higher naloxone nonresponse rates (p = 0.03). Patients with novel benzodiazepines (compared to the opioid-only group) had increased odds of requiring mechanical ventilation (aOR: 2.14; 95% CI: 1.07, 4.05) after adjusting for age, gender, race and ethnicity, and the presence of prescription benzodiazepines and/or fentanyl.
CONCLUSIONS: Nearly a third of patients with confirmed opioid overdose presenting to the ED also had concomitant benzodiazepine exposures. Those with novel benzodiazepines had significantly higher odds of intubation, suggesting greater severity of overdose.
参考来源
- Hughes A, Spungen H, Culbreth R, et al. Benzodiazepine Co-Exposure Among Patients Presenting to the Emergency Department With a Confirmed Opioid Overdose. Acad Emerg Med. 2025. PMID: 40662447. doi:10.1111/acem.70104
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。